Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, December 21, 2022
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
Uy Ear Maintained (ACAD) at Hold with Decreased Target to $15 on, Dec 21st, 2022
Uy Ear of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $17 to $15 on, Dec 21st, 2022.
Uy has made no other calls on ACAD in the last 4 months.
There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 2 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
- Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022
These are the ratings of the 2 analyists that currently disagree with Uy
- Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Thursday, November 3rd, 2022
